TKIs act via competitive inhibition at the ATP-binding site of the BCR-ABL1 oncoprotein, which results in the inhibition of phosphorylation of proteins involved in cell signal transduction (9), thereby inducing apoptosis in tumor cells. The gene discussed is ABL1; the disease is neoplasm.